As per always, very professional and succinct. The key points being the trial is still going to start in March, so FDA issues don't look a concern.
Ann: EMVision Releases its FY25 Half Yearly Report, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.79 |
Change
-0.045(2.45%) |
Mkt cap ! $153.0M | |||
| Open | High | Low | Value | Volume |
| $1.85 | $1.85 | $1.72 | $127.4K | 72.23K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8620 | $1.74 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.82 | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| EMV (ASX) Chart |